ASX BRIEFS
Welcome to 'ASX BRIEFS,' the definitive podcast for enthusiasts, investors, and professionals keen on staying ahead of the curve in the Australian Stock Exchange (ASX). Hosted by Andrew Musgrave, 'ASX BRIEFS' delves deep into the heart of Australia's financial markets, bringing you insightful conversations with the minds shaping the future of investing down under. Each episode, join Andrew as he interviews a diverse lineup of fund managers, executives, and industry insiders, offering you a unique blend of expert analysis, strategic insights, and the latest trends affecting the ASX. Whether you're a seasoned investor or just starting out, 'ASX BRIEFS' is your go-to source for comprehensive updates and thought-provoking discussions designed to inform, inspire, and empower your investment journey. Tune in to 'ASX BRIEFS' and take the pulse of Australia's financial markets right at your fingertips.
ASX BRIEFS
IDT AUSTRALIA (IDT) - Unlocking the Future of Pharma: IDT Australia's Paul McDonald on ADC Innovations, Capital Raise, and Strategic Takeover Offers
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
Unlock the future of pharmaceutical innovation with our exclusive chat featuring Paul McDonald, CEO of IDT Australia. Ever wondered how a company can navigate through a dynamic market while harnessing groundbreaking technologies? Paul divulges IDT's ambitious growth plans, recent capital raise, and the critical role of their new ADC manufacturing facility. Discover the strategic impact of a non-binding takeover offer from MyndBio, a rising star in the psychedelics industry, and what it means for IDT's future. Listen in to understand the revolutionary potential of antibody drug conjugates in targeted cancer therapy and the promising market expansion on the horizon.
Join us for a comprehensive update on IDT's ongoing projects and strategic direction. Paul offers a deep dive into how their legacy API business and advancements in the advanced therapy segment, including mRNA and ADC technologies, are setting the stage for significant revenue growth. Gain valuable insights into the dynamic environment in which IDT operates and what the future holds for this innovative pharmaceutical leader. Don't miss this engaging conversation that promises to equip you with a thorough understanding of IDT Australia's journey and aspirations.
IDT Australia's Strategic Growth Plans
Andrew MusgraveWelcome back to ASX Briefs , and today we're joined by Paul McDonald , the CEO of IDT Australia , a leader in the pharmaceutical manufacturing sector . The company has made headlines recently . It's undertaken a capital raise , received a non-binding takeover offer and secured a grant from the Victorian state government to part fund Australia's only state-of-the-art ADC manufacturing facility . Paul , thanks for joining us today and welcome to the ASX Briefs podcast .
Paul McDonaldMy pleasure . Thanks for having me today .
Andrew MusgraveNow the capital raise . Let's touch on that to start with . What are you raising the capital for and what are you aiming to achieve ?
Paul McDonaldWell , one of the things that we're working on at the moment is that we have three business verticals in API specialty , oral and advanced therapy . So we're looking to expand across all three verticals and we're looking to invest in new technology , new equipment , new formulation also expand our offering . T he advanced therapy leg is more of a newer mega trend within the pharmaceutical global market , so we're really trying to stretch ourself and bring in new technology in order to manufacture those formats .
Andrew MusgraveAnd with the takeover offer . Can you tell us more about that ?
Paul McDonaldMyndbio is a company specializes in psychedelics , but they're also growing quite rapidly and IDT have invested quite heavily into building capability in psychedelic manufacture . So a company like IDT that owns all the building and assets , all the land , with 10 buildings and 12,000 square meters , would be a very desirable company for an expanding company like MyndBio . So they've approached us with a non-binding offer and the offer stands at 15 cents . The offer today hasn't been endorsed by the board at this time , but the board have agreed to go through due diligence and operate in good faith . So there's a lot of work to go with that one , but a company like IDT would be very desirable for an expanding , growing company like MyndBio .
Andrew MusgraveAnd you're also building Australia's first commercial scale ADC facility . So can you just explain what that facility is , its strategic significance to IDT and to the broader pharmaceutical industry ?
Paul McDonaldAn Antibody Drug Conjugate is what we call a smart cancer smart chemotherapy . The antibody has been engineered to bind specifically to tumor receptors at a very specific tumor receptor , and attached to the antibody via a linker , is a very highly potent payload . So the the tumor the antibody will bind to the tumor , it'll it'll go into the cell , it'll metabolize and it will release this very toxic poison right into the into the cell of the tumor . It also has the ability to kill neighboring tumor cells as well , so that's what we call a bystander effect . The Antibody Drug Conjugate is a highly potent material . However , it's very specific , so you don't get the side effects that you do for traditional chemotherapy . It's very targeted to the tumor , it kills the tumor , kills the neighboring cells and it's highly effective .
Paul McDonaldSo the Antibody Drug Conjugate class is , is a is a technology that's gone from some 10 clinical trials in a year to over 100 today , from just a number of six or seven years . The current market for commercial products is sitting at about $13 billion and it's expected to grow to $140 billion if it continues to take over traditional modes of chemotherapy within the next 10 to 15 years . So we're building a facility , we're offering up that expertise and the moment we're doing it on very small scale with our R&D lab now building a GMP pilot scale facility . We can scale up and we can do clinical trials in phase one and we can bring some of that , more of that technology to Australia . There are already Antibody Drug Conjugate trials being performed in Australia in phase one , phase two , but having a place to manufacture them should attract more overseas investment and more overseas clients to Australia .
Andrew MusgraveAnd looking at the financial growth , you're forecasting FY24 revenue to jump by up to 91% year on year and for the company to become operating cashflow break even by year end . So is it ADC driving that growth or are there other growth drivers as well ?
Paul McDonaldYeah , the biggest driver we've got is in our API business . And the API business is our legacy business . It's been our core business for a number of decades and it's what we're known for business for a number of decades and it's what we're known for . Um , part of that API business is is high potent manufacturing . So we we do make cancer drugs , we do make uh , complex , quite complicated um API molecules . So an API is the , the active within the pharmaceutical product . So we we synthesize that in its purest form and then it gets formulated into the finished dose , being a tablet , a capsule , a liquid or a sterile injectable . So we're offering more end-to-end service now . So we're offering clients bring your new patented molecule , bring it to us , we'll design the synthesis , we'll site , we'll design it in our labs , we'll take it into our GMP facilities , scale it up , we'll make a pure form of that and then we'll process it and we'll put it into a tablet , capsule or an injectable . So offering an end-to-end solution is driving the growth . It's starting with our API . Now our specialty oral business , which is mostly neurological and mental health-based products , is having a substantial uplift on the base of making more API and converting into the tablets and capsules and the ADC and the mRNA platforms that we have in our advanced therapy segment . It's more of a lag , it's a lag pillar , so that one's one that we see rapidly growing but today has had little impact . We have manufactured some mRNA vaccines and we have manufactured some advanced therapies in our sterile injectable plant , which we only got licensed 12 months ago , but we're seeing the uptake of those and the new clients coming through now will start to benefit FY25 and FY26 through the advanced
Andrew Musgrave?
Paul McDonaldWell , we're targeting customers in the very early stage . So we're really trying to provide a service where we can take a new medicine from bench to patient and by offering that Australia has one of the fastest protocol-approving processes for first in-human . Australia has a well-established preclinical services as well , and Australia has 43 cents opportunity for 43 cents in a dollar bag for tax credit . So when you put those together , a lot of clients , a lot of overseas manufacturers or life science and biotech companies , they want to bring their technology to Australia . They want to do first in human trial phase one in in Australia .
Paul McDonaldSo if we provide a , a service to it , we're manufacturing it local , we're labeling it local , we're shipping it local and we're putting it straight into a phase one trial . So that's a set of circumstances that's very favorable to us and it's one of our biggest drawing cards . Now , if we just build all our business on phase ones , it would be really hard work . The plan there is then this to execute well , keep sticky with the client and then , as they grow they , they come back , they do more orders that in phase two , that , if they say , eventually launch into a commercial product . So we really we want to hold their clients and get to a commercial point for them and that's when we start to sort of generate the higher revenues . But it starts in the early stage and we hold them for many years .
Andrew MusgraveAnd just to wrap things up , obviously the share price has done well in recent times . So what are some of the key milestones you're looking to achieve in the next 12 to 18 months ?
Paul McDonaldWell , the share price has done well , but we're sitting here . We've just recently completed for our insurance a replacement value of $88.8 million . We're sitting on building a land that's worth about $17 million . So we've got assets here that are far greater than our current market cap and I think that the market is looking for us to hit a cash flow positive and we're progressing toward cash flow positive in FY25 . We're getting really close now . So we have done well in the market with our share price , but I feel that our market caps , like many small caps in this current environment , this is kind of undervalued and as we progress through to cash flow positive and reduce the level of predictability , I think that we should see that reflected in our share price in the near term
IDT Australia's Progress Update
Paul McDonald.
Andrew MusgraveAll right , Paul . Well , it's been great to chat . There's obviously plenty going on at the company , so we wish you all the best and look forward to further updates from IDT in the coming months .
Paul McDonaldIt's been a pleasure to speak to you today . Thank you very much .
Andrew MusgraveThat concludes this episode of ASX Briefs . Don't forget to subscribe and we look forward to catching you on our next episode .